CytoReason Collaborates with Sanofi to Initiate its Project Utilizing AI Technology for Asthma
Shots:
- CytoReason reports the initiation of a project with Sanofi by utilizing its cell-centered models and deconvolution techniques to counsel mechanistic insights for each asthma endotype
- The focus of the project is to drive a better understanding of heterogeneity in asthma patients and identify stable and reproducible asthma endotypes alongwith associated diagnostic features by using minimally invasive procedures
- CytoReason's AI platform will utilize to treat moderate to severe asthma and overlaying samples from adults and children
| Ref: PR Newswire | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com